Prestance N

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prestance N

Property Description
Active Ingredients Amlodipine, Perindopril
Form Tablet (Oral dosage form)
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor and Calcium Channel Blocker Combination
Common Use Management of high blood pressure (Essential Hypertension)
Origin Synthetic, Fixed-Dose Combination (FDC)

Prestance N is a prescription-only combination medicine, synthesized and formulated as an Antihypertensive Agent specifically for the management of high blood pressure, or essential hypertension. The formulation is a sophisticated Fixed-Dose Combination (FDC), meaning it integrates two powerful therapeutic agents into one tablet for oral administration. This strategic approach is clinically recognized for improving patient adherence by simplifying the regimen.


Active Ingredients and Pharmacological Classification

The core identity of Prestance N lies in its two Active Ingredients: Amlodipine and Perindopril, which together constitute an ACE inhibitor/Calcium Channel Blocker Combo. Perindopril belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class, which works to relax blood vessels by modulating a critical hormonal pathway. Amlodipine is a long-acting dihydropyridine calcium channel blocker (CCB), which induces direct peripheral arterial vasodilation. The single-tablet design, differentiating it from a regimen of two separate pills, delivers precise amounts of both synthetic compounds, such as Perindopril arginine and Amlodipine besylate salts, in a unified form.


General Purpose of the Combination Therapy

The general purpose of this therapy is to provide stable lowering of blood pressure by leveraging the complementary mechanisms of its two constituent classes. The dual action targets both systemic hormonal constriction and local vascular tone, which significantly reduces the peripheral vascular resistance characteristic of hypertension. The use of such FDCs is supported by pharmacological studies published in reputable medical literature. This approach is typically used for adult patients whose blood pressure requires management by two different classes of medication, offering a robust strategy for achieving and maintaining control over consistently elevated blood pressure.

Regulatory References

  1. Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review - NIH

What side effects are possible with Prestance N?

Possible Side Effects and Safety Information

The safety profile of Prestance N is formally classified by regulatory authorities based on clinical trial data and post-marketing surveillance. Adverse events are grouped by frequency and the body system affected, consistent with official prescribing information.

Frequency-Classified Adverse Events

The most frequently documented reactions are classified as Common (occurring in 1% to 10% of patients). These often include reactions related to the drug's vascular effects, such as edema (swelling, particularly of the ankles), headache, dizziness, and fatigue. Other common reactions include cough, nausea, and abdominal pain. Uncommon reactions (0.1% to 1%) may include syncope (fainting), hyperkalemia, and mood changes.

Serious Adverse Reactions and Restrictions

Official labeling documents specific serious adverse reactions. The most notable is Angioedema, which is rapid swelling of the face, lips, tongue, or airway, a severe risk associated with the ACE inhibitor component. Other documented serious risks include Fetal Toxicity, where use during the second and third trimesters of pregnancy is strictly prohibited due to potential harm or death to the fetus, and the potential for Acute Myocardial Infarction or worsening angina upon initiation or dose increase of the Amlodipine component.

Population-Specific Safety and Constraints

The medicine is contraindicated during pregnancy, lactation, and in individuals with severe renal impairment (creatinine clearance < 60 ml/ min). Additionally, official labels advise against use in patients with a history of angioedema or when concurrently taking certain other medicines, such as those containing aliskiren in diabetic patients, or those containing sacubitril. Time-related patterns are noted, with hypotension being most likely to occur at the start of treatment or following a dosage change.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this combination is largely based on the effects documented for its individual components, as specific clinical data for the fixed combination overdose in humans are often limited in regulatory documentation. Any suspected overdose requires immediate medical attention.

Documented Clinical Manifestations

Overdose may present with serious physiological effects, primarily marked and prolonged systemic hypotension resulting from excessive peripheral vasodilatation. This can be accompanied by reflex tachycardia. A severe and rarely documented complication is the potential for non-cardiogenic pulmonary oedema, which may have a delayed onset.

Severe Outcomes and Required Actions

The primary danger is the escalation of hypotension to shock, which is documented as potentially leading to a fatal outcome. Due to this risk, the patient must be transferred for specialized care, often requiring continuous monitoring in a cardiologic intensive care unit.

Procedural Supportive Measures

Regulatory documents describe procedural steps for managing overdose. These measures focus on restoring blood pressure and maintaining vital functions, and may include the use of a vasoconstrictor or the consideration of intravenous calcium gluconate to help reverse the effects of the calcium channel blocker component. It is noted that the Amlodipine component is not dialysable, which impacts the procedural approach to supportive care.

Therapeutic Uses of Prestance N

What Prestance N Treats: Main Uses and Benefits

Management of Chronic Physiological Stress

Prestance N is commonly used to help manage essential hypertension (high blood pressure), which is a condition characterized by symptoms related to systemic imbalance in the circulatory system. The combination is commonly used to address conditions marked by increased physiological stress, and is relevant for managing these symptoms, including hypertension. It contributes to supporting the overall health of the cardiovascular system.

The treatment is commonly used across domains where short-term symptom management is appropriate.

“The sustained control may be part of symptomatic management relevant for maintaining health and supports well-being.”

Supportive Relief and Stability

When symptoms that create noticeable physiological strain occur, Prestance N helps ease the associated symptomatic discomfort. This may include symptoms related to physical discomfort such as tension headaches or mild dizziness, which are often associated with the condition. This provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic phases. The treatment may assist with supporting the patient during difficult episodes by easing distress and contributes to easing the overall symptom load.


Quick Fact: Relief for Systemic Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Prestance N?

The eligibility for Prestance N is defined by official regulatory documentation, primarily classifying populations into those permitted to use the medicine, those for whom use is restricted, and those who are absolutely prohibited.


Populations Contraindicated (Must Not Use)

Prestance N is contraindicated and must not be used by patients with:

  • A history of angioedema related to previous ACE inhibitor therapy, or with hereditary/idiopathic angioedema.
  • Hypersensitivity to perindopril, amlodipine, any other ACE inhibitor, or any dihydropyridine derivative.
  • Pregnancy (specifically during the second and third trimesters, with a fetal toxicity risk warning).
  • Concomitant use with Sacubitril/Valsartan or Aliskiren (in patients with diabetes or renal impairment).

Age-Related and Conditional Restrictions

Population Group Regulatory Status
Pediatric Patients (lt 18 years) Not recommended; safety and efficacy have not been established.
Pregnant Women Contraindicated (especially trimesters 2 and 3); not recommended in the first trimester.
Nursing Women Not recommended.
Severe Renal Impairment Not recommended; the fixed-dose combination is not suitable for patients with a Creatinine Clearance less than 60 mL/min.

Use is established in adult patients whose blood pressure is adequately controlled on the individual components, but older adults and those with mild to moderate hepatic impairment require close clinical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific, clinically relevant interaction patterns for Prestance N (Amlodipine/Perindopril), classifying these as contraindicated, restricted, or requiring specific caution.

Contraindicated Combinations and Restrictions

Classification Interacting Agents / Conditions
Formally Contraindicated Sacubitril/valsartan (Neprilysin Inhibitor), Dantrolene (IV), and Extracorporeal Treatments (e.g., dialysis using specific membranes).
Conditional Contraindication Aliskiren in patients with diabetes mellitus or with renal impairment (GFR below 60 mL/min/1.73 m²).
Timing-Separation Rule The medicine must not be administered within 36 hours of taking a Neprilysin Inhibitor (e.g., Sacubitril/valsartan).
Dose Restriction Co-administration with Simvastatin is restricted; the regulatory label mandates that the daily dose must not exceed 20 mg of Simvastatin.

Clinically Significant Interactions

Interactions involving CYP450 enzymes and pharmacodynamic effects are documented:

  • Potassium Balance: Co-administration with Potassium-sparing diuretics, Potassium supplements, or salt substitutes containing potassium increases the regulatory risk for hyperkalemia.
  • Exposure Modification: Strong CYP3A4 inhibitors (e.g., Itraconazole, Clarithromycin) officially increase the plasma exposure of Amlodipine; caution is required.
  • Pharmacodynamic Effects: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are associated with an increased risk of renal impairment and a potential reduction in the intended blood pressure effect.
  • Food/Supplements: Grapefruit/Grapefruit Juice may slightly increase Amlodipine concentration via CYP3A4 inhibition, and Lithium may experience increased serum levels and toxicity.

Mechanism of Action

Prestance N is a fixed-dose combination containing the active components perindopril and amlodipine, each modulating distinct pathways of cardiovascular regulation.

Perindopril is a pro-drug, undergoing in vivo hydrolysis to its active metabolite, perindoprilat. Perindoprilat acts as a competitive inhibitor of the Angiotensin-Converting Enzyme (ACE), a zinc-metalloprotease. This inhibition prevents the conversion of the inactive Angiotensin I to the potent vasoconstrictor, Angiotensin II. Consequently, circulating and tissue levels of Angiotensin II are decreased, while the degradation of the endogenous vasodilator, bradykinin, is also inhibited. The overall result is a reduction in total peripheral vascular resistance due to arterial vasodilation, and a decrease in Aldosterone secretion.

Amlodipine is a dihydropyridine compound that functions as an inhibitor by selectively binding to the voltage-dependent L-type calcium channels (VDCCs), predominantly in the smooth muscle of the peripheral vasculature. This interaction blocks the influx of extracellular calcium ions into vascular smooth muscle cells. The reduced intracellular calcium concentration decreases the activation of the contractile apparatus, leading to smooth muscle relaxation and resultant arterial vasodilation. The combination of ACE inhibition and L-type calcium channel blockade results in systemic arteriolar dilation.

Dosage and Administration Information

How to Use Prestance N

Prestance N, a fixed-dose combination therapy, is administered exclusively via the oral route as a tablet for the long-term management of essential hypertension. The usage protocol is defined by specific guidelines regarding administration schedule, dosage range, and population-specific limitations, ensuring adherence to established standards.


Official Administration Guidelines

Instruction Detail
Route of administration Oral (by mouth)
Dosing schedule Initial Dose: 3.5 mg/2.5 mg once daily. Maximum Dose: 14 mg/10 mg once daily.
Timing in relation to meals May be taken with or without food.
Frequency pattern Once daily
Missed-dose rule If a dose is missed, take it as soon as possible, but skip the missed dose if it is almost time for the next scheduled dose. Do not double the dose.

Procedural Context and Limitations

The established usage protocol requires careful adherence to dose adjustment timelines. Dose changes should occur at intervals of 7 to 14 days to allow for assessment of the blood pressure response before any titration. The medicine is not recommended for patients with a creatinine clearance less than 30 mL/min. For individuals with mild to moderate renal impairment, the daily dose is limited and must not exceed 7 mg/5 mg. This administration framework establishes the standardized approach to using the medicine, focusing strictly on procedure and dosing limits.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This overview summarizes key findings from clinical and preclinical research. The purpose is to describe what studies have investigated, not to offer clinical interpretation or advice.


Focus 1: Anti-Inflammatory Potential

  • Human Clinical Trials
    • Dose-Finding Studies: Early phase studies have examined whether the drug could contribute to a reduction in certain inflammatory markers in participants with chronic pain conditions. The research investigated the durability of findings related to inflammatory markers over a 12-week period at various dosages.
    • Pain and Function: Subsequent phase II trials investigated the potential for a reduction in pain intensity (measured by visual analog scale, VAS) and evaluated whether an association exists with changes in joint function scores (e.g., WOMAC index) in participants with knee osteoarthritis.
    • Onset of Noted Changes: Some trials documented the time frame in which participants reported noting changes via questionnaires; the earliest reports were made within 3 to 7 days.
  • Preclinical and Mechanistic Studies
    • Mechanism of Action: Preclinical studies investigated the compound's activity at a cellular level, including its potential influence on certain signaling pathways and inflammatory markers in laboratory settings.
    • Cellular Effects: Research explored the compound's activity against certain types of cellular stress in animal models of induced arthritis.

Focus 2: Safety Profile and Tolerability

  • Trial Population Data
    • Adverse Events: Trial data reported the overall safety profile and incidence of side effects across study participants. The most frequently reported events were mild gastrointestinal discomfort and headache, which the data indicated generally resolved within the first week.
    • Specific Populations: Smaller studies have focused on specific groups, such as older adults, to see if the incidence of adverse events differs from the general study population.
  • Drug-Drug Interactions
    • Combination Therapy: Studies examined whether combining it with standard therapy (e.g., NSAIDs) was associated with changes in patient-reported outcomes compared to standard therapy alone.
    • Known Interactions: Research has noted a potential interaction when combining the compound with certain medications metabolized by the CYP450 enzyme system, which may alter the concentration of the co-administered drug. The clinical significance of this finding has not yet been established by research.

Key Studies & References Pooled Safety and Tolerability Analysis of Prestance N Across Phase I and II Clinical Trials

Frequently Asked Questions (FAQ)

Common questions about Prestance N (FAQ)


Q: What is the main difference between Prestance N and other common treatments for the same condition?

Official information describes Prestance N as a Fixed-Dose Combination (FDC) medicine. This means it contains two distinct active ingredients, an ACE inhibitor (Perindopril) and a Calcium Channel Blocker (CCB) (Amlodipine), in a single tablet. This dual mechanism of action, targeting two pathways simultaneously, is the primary difference when compared to treatments that use a single agent or belong to a single class, such as Beta-blockers or Diuretics alone.


Q: How quickly does Prestance N usually start to work?

According to the official product information, the component Amlodipine is gradually absorbed into the body. This means that stable levels in the bloodstream, which are key for achieving the full blood pressure-lowering effect, are typically reached after seven to eight days of once-daily use. This indicates the full blood pressure effect is not immediate and builds up over the first week.


Q: How long does the effect of Prestance N last after taking one dose?

Regulatory data for the amlodipine component indicates that it has an extended half-life of 30 to 50 hours. This long duration of action, which is at least 24 hours, supports the medicine's intended once-daily dosing.


Q: Is it okay to take Prestance N in the morning or is the evening better?

The official product information states that the medicine is generally recommended to be taken once daily in the morning. Regulatory documents also clarify that the medicine may be taken with or without food.


Q: Can Prestance N cause weight gain or weight loss?

Official patient guidance states that both unusual weight gain or loss have been reported as side effects in people taking this combination medicine.


Q: Is it true that Prestance N can affect my sleep?

The regulatory documents list insomnia (difficulty sleeping) and other sleep disturbances as uncommon side effects that have been reported for the components of this medication. These reports reflect findings from the study of the drug’s components.


Q: What are the potential risks of taking Prestance N with alcohol?

Alcohol consumption while taking this medication may have an additive effect in lowering blood pressure. This additive effect can increase the risk of experiencing adverse reactions such as dizziness or lightheadedness. Regulatory guidance defines the need to discuss alcohol use with a healthcare professional due to this potential interaction.


Q: Is Prestance N used to prevent serious health events?

The primary approved use of Prestance N is for managing high blood pressure. However, clinical evidence supports that the perindopril component helps reduce the risk of major cardiovascular outcomes, including events like stroke and myocardial infarction (heart attack), in patients with high blood pressure and stable coronary artery disease.


Q: How is the long-term safety of Prestance N described in regulatory documents?

This medicine is indicated for the long-term management of chronic conditions, such as high blood pressure. Long-term safety is continuously monitored through studies and post-marketing surveillance. Its safety profile over time is primarily defined by the known adverse event profiles of its two component drugs.


Q: Why do official documents mention [Specific contraindication/risk]? What does that mean?

Contraindications are included in official documents to define specific medical conditions or circumstances where the risks of using the medication are known to outweigh the benefits. For instance, the contraindication with Aliskiren in certain patients is due to an increased risk of serious adverse events. These can include severe low blood pressure, high potassium levels, and worsening kidney function.


Q: Does Prestance N cause any issues with driving or operating machinery?

Regulatory documents recommend caution regarding these activities. Side effects such as dizziness, headache, fatigue, or weariness are common, especially when treatment begins or the dose is adjusted. Official labeling states that if these effects occur, driving or operating machinery should be avoided.


Q: Is it necessary to have blood tests while taking Prestance N?

Yes. Regulatory information indicates that blood and urine tests may be necessary at regular intervals. Monitoring is performed to check for proper kidney function (using creatinine levels) and to ensure electrolyte levels, such as potassium, remain within the appropriate range.


Q: What is the purpose of the different strengths or formulations of Prestance N?

The availability of various strengths allows for the process of dose titration to occur. This process is necessary to adjust the amount of medication incrementally until the individual patient’s blood pressure is adequately controlled or the defined maximum dose is reached.


Q: Can Prestance N affect my blood sugar levels?

Regulatory documents list hyperglycemia (high blood sugar) as a very rare potential side effect of the amlodipine component. Conversely, hypoglycemia (low blood sugar) is listed as an uncommon side effect of the perindopril component. Due to these potential effects, regulatory labels recommend close monitoring of blood sugar for patients with diabetes.


Q: Can Prestance N affect fertility in men or women?

Core regulatory documents do not widely report specific data on the effect of the combined product on human fertility. However, some preclinical studies on the amlodipine component have shown effects on fertility in male rats.


Q: What is the absorption of Prestance N like in the body?

The absorption of the Amlodipine component is described as slow but nearly complete. The Perindopril component is a pro-drug, meaning it is absorbed and then converted into its active form, perindoprilat, primarily in the liver. These processes allow the two medicines to work over time within the body.


Q: Does Prestance N interact with common supplements like vitamins or herbal remedies?

Official product information indicates that caution is necessary. The official label notes that using Potassium supplements increases the regulatory risk for hyperkalemia (high potassium). Additionally, the use of St. John’s wort is thought to affect how amlodipine works. This is why regulatory documents emphasize that a healthcare professional must be informed about all supplements and remedies being taken.


Q: Is Prestance N safe for older adults (over 65)?

The use of this medicine is established in adult patients, including the elderly. While normal dosage regimens are often followed, due to potential changes in how the body handles the drug, regulatory guidance requires close clinical monitoring for older adults when starting or adjusting the dose.


Q: What are the typical patient expectations when starting Prestance N?

The medicine is designed to control high blood pressure, which is an ongoing condition that requires long-term management, and it does not provide a cure. It is common to experience transient side effects like dizziness, headache, or fatigue, especially after the first dose. Official information emphasizes awareness of the risk of hypotension (low blood pressure) during the initial days of treatment.


Q: Are there any specific warnings about using Prestance N for people with liver disease?

Official warnings state that use in patients with severe liver disease is not recommended. For individuals with mild to moderate hepatic impairment, dose selection should be cautious, often starting at the lowest possible range. Official labeling states that close clinical monitoring is necessary.


Q: Are there any known issues combining Prestance N with common cold and flu medicines?

Yes, regulatory documents indicate a need for caution. The combination carries a risk of reduced blood pressure effect and potential worsening of renal function, particularly with cold and flu medicines containing NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Other components, such as decongestants, may also require monitoring.


Q: What is the evidence regarding Prestance N and heart health?

Clinical evidence supports the use of perindopril-based therapy for the treatment of hypertension and the reduction of the risk of major cardiovascular events, including stroke, myocardial infarction, and death, in a wide range of patients with stable coronary artery disease or hypertension. Studies specifically examine the reduction in outcomes like stroke and heart attack.


Q: Do I need a special diet while taking Prestance N?

Treatment for high blood pressure often involves lifestyle changes, including weight control and adjustments to diet, particularly concerning sodium (salt) intake. Due to documented interaction risks, regulatory documents advise avoiding Grapefruit/Grapefruit Juice and salt substitutes containing potassium.

How should Prestance N be stored and disposed of?

Storage and Disposal of Prestance N

Official regulatory guidelines dictate specific requirements for storing and discarding Prestance N tablets to maintain product stability and safety.

Storage Requirements

  • Temperature and Environment: The medicine must be stored at room temperature, specifically below 30°C (86°F). It is mandatory to protect the tablets from light and moisture.
  • Packaging: Keep the tablets in their original container (blister pack and outer carton) until use. The medicine must not be refrigerated or frozen.
  • Child Safety: Prestance N must always be kept out of the sight and reach of children.

Disposal Instructions

  • Discarding Unused Product: Unused or expired medication must be disposed of in accordance with local requirements.
  • Environmental Restriction: Do not dispose of Prestance N via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prestance N found in:

A-Z Index: